vaccinessssssssssssssssssss_1

India begins human trials of its first homegrown coronavirus vaccine

pharmafile | July 21, 2020 | News story | Manufacturing and Production COVID, COVID-19, Vaccine, coronavirus 

India has begun human trials of its first internally developed vaccine for COVID-19.

The Indian Council of Medical Research have allowed both Phase 1 and 2 human trials of Covaxin, the experimental vaccine developed by Bharat Biotech. Lokesh Sharma, the Council’s media coordinator, said: “Trials at some sites began yesterday or before, at some places it will begin today and at some sites it will start tomorrow.”

Bharat Biotech is collaborating with both the Council and the National Institute of Virology, and the trials have begun with 100 of the 375 volunteers in 12 pre-selected hospitals for the Phase I study.  This will assess if the vaccine candidate is safe in humans.

Randeep Guleria, the Director of the All India Institute of Medical Sciences, said: “We are starting the phase-1 of the trial. A second dose will be given after 14 days and then we will collect blood samples after various intervals and we will decide, based on the analysis, what is the effectiveness of this vaccine.”

Bharat Biotech has previously delivered more than 4 billion doses of various vaccines worldwide for diseases like H1N1 and rotavirus.

Conor Kavanagh

Related Content

Gilead’s Veklury recommended by NICE for COVID-19 treatment

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …

GSK shares new data for RSV vaccine Arexvy

GSK announced positive results from its phase 3 trial which assessed the immune response and …

Latest content